Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 3
1981 9
1982 5
1983 6
1984 4
1985 11
1986 6
1987 8
1988 13
1989 33
1990 20
1991 25
1992 29
1993 22
1994 36
1995 35
1996 43
1997 52
1998 43
1999 46
2000 47
2001 52
2002 90
2003 113
2004 131
2005 141
2006 170
2007 192
2008 264
2009 235
2010 274
2011 379
2012 433
2013 484
2014 529
2015 615
2016 737
2017 775
2018 839
2019 937
2020 1108
2021 1279
2022 875
Text availability
Article attribute
Article type
Publication date

Search Results

9,966 results
Results by year
Filters applied: . Clear all
Page 1
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ, Tuekprakhon A, Nutalai R, Wang B, Dijokaite A, Khan S, Avinoam O, Bahar M, Skelly D, Adele S, Johnson SA, Amini A, Ritter TG, Mason C, Dold C, Pan D, Assadi S, Bellass A, Omo-Dare N, Koeckerling D, Flaxman A, Jenkin D, Aley PK, Voysey M, Costa Clemens SA, Naveca FG, Nascimento V, Nascimento F, Fernandes da Costa C, Resende PC, Pauvolid-Correa A, Siqueira MM, Baillie V, Serafin N, Kwatra G, Da Silva K, Madhi SA, Nunes MC, Malik T, Openshaw PJM, Baillie JK, Semple MG, Townsend AR, Huang KA, Tan TK, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Constantinides B, Webster H, Crook D, Pollard AJ, Lambe T; OPTIC Consortium; ISARIC4C Consortium, Paterson NG, Williams MA, Hall DR, Fry EE, Mongkolsapaya J, Ren J, Schreiber G, Stuart DI, Screaton GR. Dejnirattisai W, et al. Among authors: zhou d. Cell. 2022 Feb 3;185(3):467-484.e15. doi: 10.1016/j.cell.2021.12.046. Epub 2022 Jan 4. Cell. 2022. PMID: 35081335 Free PMC article.
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, Liu C, Mentzer AJ, Supasa P, Duyvesteyn HME, Das R, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Constantinides B, Webster H, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Crook D, Pollard AJ, Lambe T, Goulder P, Paterson NG, Williams MA, Hall DR; OPTIC Consortium; ISARIC4C Consortium, Fry EE, Huo J, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Tuekprakhon A, et al. Among authors: zhou d. Cell. 2022 Jul 7;185(14):2422-2433.e13. doi: 10.1016/j.cell.2022.06.005. Epub 2022 Jun 9. Cell. 2022. PMID: 35772405 Free PMC article.
SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis.
Allotey J, Chatterjee S, Kew T, Gaetano A, Stallings E, Fernández-García S, Yap M, Sheikh J, Lawson H, Coomar D, Dixit A, Zhou D, Balaji R, Littmoden M, King Y, Debenham L, Llavall AC, Ansari K, Sandhu G, Banjoko A, Walker K, O'Donoghue K, van Wely M, van Leeuwen E, Kostova E, Kunst H, Khalil A, Brizuela V, Broutet N, Kara E, Kim CR, Thorson A, Oladapo OT, Zamora J, Bonet M, Mofenson L, Thangaratinam S; PregCOV-19 Living Systematic Review Consortium. Allotey J, et al. Among authors: zhou d. BMJ. 2022 Mar 16;376:e067696. doi: 10.1136/bmj-2021-067696. BMJ. 2022. PMID: 35296519 Free PMC article.
Lipid-Head-Polymer-Tail Chimeric Vesicles.
Hu K, Cheng A, Zhou D, Luo Y, Zhang G. Hu K, et al. Among authors: zhou d. Macromol Rapid Commun. 2022 Jul 8:e2200124. doi: 10.1002/marc.202200124. Online ahead of print. Macromol Rapid Commun. 2022. PMID: 35803897
Effect of Early vs Late Supplemental Parenteral Nutrition in Patients Undergoing Abdominal Surgery: A Randomized Clinical Trial.
Gao X, Liu Y, Zhang L, Zhou D, Tian F, Gao T, Tian H, Hu H, Gong F, Guo D, Zhou J, Gu Y, Lian B, Xue Z, Jia Z, Chen Z, Wang Y, Jin G, Wang K, Zhou Y, Chi Q, Yang H, Li M, Yu J, Qin H, Tang Y, Wu X, Li G, Li N, Li J, Pichard C, Wang X. Gao X, et al. Among authors: zhou d. JAMA Surg. 2022 May 1;157(5):384-393. doi: 10.1001/jamasurg.2022.0269. JAMA Surg. 2022. PMID: 35293973 Free PMC article. Clinical Trial.
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, Xie W, Zhou D, Huang X, Wang Y, Xu G, Lu Y, Wei J, Mai W, Ye X, Meng H, Shen Y, Huang J, Yu W, Sun J, Sheng J, Yan X, Jin J, Zhu HH. Wang H, et al. Among authors: zhou d. Lancet Haematol. 2022 Jun;9(6):e415-e424. doi: 10.1016/S2352-3026(22)00106-5. Epub 2022 May 2. Lancet Haematol. 2022. PMID: 35512726 Clinical Trial.
9,966 results